{"nctId":"NCT03201003","briefTitle":"ARTEMIS Peanut Allergy In Children","startDateStruct":{"date":"2017-06-12","type":"ACTUAL"},"conditions":["Peanut Allergy"],"count":175,"armGroups":[{"label":"AR101","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: AR101 powder provided in capsules & sachets"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo powder provided in capsules & sachets"]}],"interventions":[{"name":"AR101 powder provided in capsules & sachets","otherNames":[]},{"name":"Placebo powder provided in capsules & sachets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Age 4 to 17 years, inclusive\n* Clinical history of allergy to peanuts\n* Serum SPT ≥ 3 mm greater than control and/or psIgE ≥ 0.35 kUa/L\n* Dose limiting symptoms after consuming a single dose of peanut protein ≤ 300 mg\n* Written informed consent from the subject's parent/guardian\n* Written assent from the subject as appropriate (per local regulatory requirements)\n* Use of effective birth control by sexually active female subjects of childbearing potential\n\nKey Exclusion Criteria:\n\n* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension\n* History of severe asthma (NHLBI criteria steps 5 or 6), or mild to moderate asthma (2007 NHLBI criteria steps 1-4) that is uncontrolled or difficult to control\n* History of severe or life threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening\n* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology\n* History of a mast cell disorder, including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (e.g., cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema\n* Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Proportion of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 1000 mg in the Exit Oral Food Challenge.","description":"The proportion of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild symptoms at the Exit Oral Food Challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Oral Food Challenge","description":"The proportion of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild symptoms at the Exit Oral Food Challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 300 mg in the Exit Oral Food Challenge.","description":"The proportion of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild symptoms at the Exit Oral Food Challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Severity of Symptoms at Any Challenge Dose During the Peanut Exit Oral Food Challenge","description":"The maximum severity of symptoms on 4 levels: 0-None, 1-Mild, 2-Moderate, 3-Severe or higher (severe, life threatening, fatal) observed in the DBPCFC at any dose (1000 mg or lower)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":132},"commonTop":["Abdominal pain","Cough","Pruritus","Nausea","Throat irritation"]}}}